EUVIMEDEUVIMED entdecken
Crossref

SRS188 - National outcomes in simultaneous pancreas–kidney transplantation: the role of HLA mismatch and induction therapy

Abdullah Malik, Jenni Banks, Claire Counter, Lewis Simmonds, Samuel Tingle, Sanjay Sinha, Anand Muthasamy, Andrew Sutherland, John Casey, Martin Drage, David van Dellen, Chris Callaghan und 7 weitere

British Journal of Surgery · 27.03.2026 · 113 (Supplement_2)

DOI: 10.1093/bjs/znag018.176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 27.03.2026. Verfasst von Abdullah Malik und 18 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Simultaneous pancreas–kidney (SPK) transplantation offers the best long-term survival for selected patients with insulin-dependent diabetes and end-stage renal disease. However, determinants of pancreas graft survival remain incompletely defined, particularly the role of HLA mismatch and induction therapy.

Methods

We analysed all SPK transplants in the UK between April 2007–March 2019 using data extracted from the UK Transplant Registry. Multivariable Cox proportional hazards models assessed the impact of locus-specific HLA mismatch and induction therapy (Alemtuzumab versus Basiliximab) on pancreas, kidney, and patient survival, adjusted for donor, recipient, and transplant factors.

Results

Among 1705 SPK recipients, pancreas graft survival was 88.6, 81.3, and 72.7% at 1, 5, and 10 years, respectively. Kidney graft and patient survival at 10 years were 76.7 and 75.3%. Independent predictors of pancreas graft loss included donor age, cold ischaemic time, and HLA-DQ mismatch. Unexpectedly, recipients with a DQ mismatch had improved long-term pancreas graft survival compared with those with no mismatch (HR 0.75, 95% c.i. 0.59–0.94, P = 0.033). This protective effect was not observed for kidney or patient outcomes. Induction therapy type did not significantly influence survival on adjusted analyses.

Conclusions

In this first national analysis of HLA and induction in SPK transplantation, DQ mismatch was associated with superior long-term pancreas graft survival. This novel finding warrants mechanistic investigation and may inform future allocation and immunogenetic strategies in pancreas transplantation.

Zitieren

APA

Malik, A., Banks, J., Counter, C., Simmonds, L., Tingle, S., Sinha, S., Muthasamy, A., Sutherland, A., Casey, J., Drage, M., Dellen, D. V., Callaghan, C., Elker, D., Manas, D., Pettigrew, G., Russell, N., Sheerin, N., Wilson, C., & White, S. (2026). SRS188 - National outcomes in simultaneous pancreas–kidney transplantation: the role of HLA mismatch and induction therapy. British Journal of Surgery, 113(Supplement_2). https://doi.org/10.1093/bjs/znag018.176

Vancouver

Malik A, Banks J, Counter C, Simmonds L, Tingle S, Sinha S, et al. SRS188 - National outcomes in simultaneous pancreas–kidney transplantation: the role of HLA mismatch and induction therapy. British Journal of Surgery. 2026;113(Supplement_2). doi:10.1093/bjs/znag018.176

BibTeX
@article{Malik2026,
  author = {Malik, Abdullah and Banks, Jenni and Counter, Claire and Simmonds, Lewis and Tingle, Samuel and Sinha, Sanjay and Muthasamy, Anand and Sutherland, Andrew and Casey, John and Drage, Martin and Dellen, David van and Callaghan, Chris and Elker, Doruk and Manas, Derek and Pettigrew, Gavin and Russell, Neil and Sheerin, Neil and Wilson, Colin and White, Steven},
  title = {SRS188 - National outcomes in simultaneous pancreas–kidney transplantation: the role of HLA mismatch and induction therapy},
  journal = {British Journal of Surgery},
  year = {2026},
  volume = {113},
  number = {Supplement_2},
  doi = {10.1093/bjs/znag018.176}
}
Kostenlos starten →